"Pharmacogenomic Variants" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Naturally occurring genetic variations associated with drug response (e.g., dosage, extent and rate of metabolic processes). While these variants are not markers for GENETIC PREDISPOSITION TO DISEASE they influence PHARMACOKINETICS and pharmacodynamics and often occur on genes encoding drug metabolism enzymes and transporters (e.g., ANGIOTENSIN CONVERTING ENZYME; CYTOCHROME P-450 CYP2D6).
| Descriptor ID |
D000071184
|
| MeSH Number(s) |
G05.365.795.446
|
| Concept/Terms |
Pharmacogenomic Variants- Pharmacogenomic Variants
- Pharmacogenomic Variant
- Variant, Pharmacogenomic
- Variants, Pharmacogenomic
- Pharmacokinetic Genetic Variants
- Genetic Variant, Pharmacokinetic
- Genetic Variants, Pharmacokinetic
- Pharmacokinetic Genetic Variant
- Pharmacogenetic Variants
- Pharmacogenetic Variant
- Variant, Pharmacogenetic
- Variants, Pharmacogenetic
|
Below are MeSH descriptors whose meaning is more general than "Pharmacogenomic Variants".
Below are MeSH descriptors whose meaning is more specific than "Pharmacogenomic Variants".
This graph shows the total number of publications written about "Pharmacogenomic Variants" by people in this website by year, and whether "Pharmacogenomic Variants" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 1 | 0 | 1 |
| 2017 | 11 | 8 | 19 |
| 2018 | 5 | 4 | 9 |
| 2019 | 6 | 1 | 7 |
| 2020 | 1 | 1 | 2 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Pharmacogenomic Variants" by people in Profiles.
-
Pharmacogenomic landscape of COVID-19 therapies from Indian population genomes. Pharmacogenomics. 2021 07; 22(10):603-618.
-
Pharmacogenetics Approach for the Improvement of COVID-19 Treatment. Viruses. 2021 03 05; 13(3).
-
Advances in the Pharmacogenomics of Antiplatelet Therapy. Am J Ther. 2020 Sep/Oct; 27(5):e477-e484.
-
COVID-19: A Concern for Cardiovascular Disease Patients. Cardiovasc Toxicol. 2020 10; 20(5):443-447.
-
Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients. Eur Heart J Cardiovasc Pharmacother. 2020 07 01; 6(4):203-210.
-
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2019 08 26; 12(16):1521-1537.
-
Psychopharmacology and ethnicity: A comparative study on Senegalese and Italian men. World J Biol Psychiatry. 2020 04; 21(4):300-307.
-
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. J Antimicrob Chemother. 2019 04 01; 74(4):1035-1043.
-
The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH Study. Clin Pharmacol Ther. 2019 08; 106(2):450-457.
-
Polymorphisms associated with anti-TNF drugs response in patients with psoriasis and psoriatic arthritis. J Eur Acad Dermatol Venereol. 2019 Apr; 33(4):e175-e177.